Prognostic significance of metastatic lymph node ratio in patients with gastric cancer after curative gastrectomy: a single-center retrospective study

References

• Eusebi LH, Telese A, Marasco G, et al. Gastric cancer prevention strategies: a global perspective. J Gastroenterol Hepatol. 2020;35(9):1495–1502.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published correction appears in CA cancer J clin. 2020 jul;70(4):313]. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Zhou ML, Kang M, Li GC, Guo XM, et al. Postoperative chemoradiotherapy versus chemotherapy for R0 resected gastric cancer with D2 lymph node dissection: an up-to-date meta-analysis. World J Surg Oncol. 2016;14(1):209.
   PubMed Web of Science ®Google Scholar
• Chen Y, Xu S, Huang C, et al. Cancer cells invasion to the gastric bare area adipose tissue: a poor prognostic predictor for gastric cancer. World J Surg Onc. 2020;18(1):300.
   PubMed Web of Science ®Google Scholar
• He Y, Mao M, Shi W, et al. Development and validation of a prognostic nomogram in gastric cancer with hepatitis B virus infection. J Transl Med. 2019;17(1):98.
   PubMed Web of Science ®Google Scholar
• Agnes A, Biondi A, Cananzi FM, et al. Ratio-based staging systems are better than the 7th and 8th editions of the TNM in stratifying the prognosis of gastric cancer patients: a multicenter retrospective study. J Surg Oncol. 2019;119(7):948–957.
   PubMed Web of Science ®Google Scholar
• Hung M, Xu J, Nielson D, et al. Evaluating the prediction of breast cancer survival using lymph node ratio. J Breast Cancer. 2018;21(3):315–320.
   PubMed Web of Science ®Google Scholar
• Zhang CH, Li YY, Zhang QW, et al. The prognostic impact of the metastatic lymph nodes ratio in colorectal cancer. Front Oncol. 2018;8:628.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Sun Y, Zhang W, et al. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: a single-center retrospective study. Asia‐Pac J Clin Oncol. 2020;16(3):180–186.
   PubMed Web of Science ®Google Scholar
• Díaz Del Arco C, Estrada Muñoz L, Sánchez Pernaute A, et al. Towards standardization of lymph-node ratio classifications: validation and comparison of different lymph node ratio classifications for predicting prognosis of patients with resected gastric cancer. Ann Diagn Pathol. 2021;52:151738.
   PubMed Web of Science ®Google Scholar
• Kano K, Yamada T, Yamamoto K, et al. Association between lymph node ratio and survival in patients with pathological stage II/III gastric Cancer. Ann Surg Oncol. 2020;27(11):4235–4247.
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259.
   PubMed Web of Science ®Google Scholar
• Liao R, Tang ZW, Li DW, et al. Preoperative neutrophil-to-lymphocyte ratio predicts recurrence of patients with single-nodule small hepatocellular carcinoma following curative resection: a retrospective report. World J Surg Onc. 2015;13(1):265.
   PubMed Web of Science ®Google Scholar
• Hori SS, Lutz AM, Paulmurugan R, et al. A Model-Based personalized cancer screening strategy for detecting early-stage tumors using blood-borne biomarkers. Cancer Res. 2017;77(10):2570–2584.
   PubMed Web of Science ®Google Scholar
• Shekarriz R, Faghani S, Tafazoli A, et al. The correlation between phospholipase C epsilon (PLCE1) gene polymorphisms and risk of gastric adenocarcinoma in Iranian population. Int J Hematol Oncol Stem Cell Res. 2019;13(3):108–115.
   PubMedGoogle Scholar
• Li Y, Wei Y, He Q, et al. Clinicopathological and prognostic significance of high circulating lymphocyte ratio in patients receiving neoadjuvant chemotherapy for advanced gastric cancer. Sci Rep. 2018;8(1):6223.
   PubMed Web of Science ®Google Scholar
• Jia X, Lu M, Rui C, et al. Consensus-Expressed CXCL8 and MMP9 identified by meta-analyzed perineural invasion gene signature in gastric cancer microarray data. Front Genet. 2019;10:851.
   Google Scholar
• Vedeld HM, Goel A, Lind GE. Epigenetic biomarkers in gastrointestinal cancers: the current state and clinical perspectives. Semin Cancer Biol. 2018;51:36–49.
   PubMed Web of Science ®Google Scholar
• Deng J, Liu J, Wang W, et al. Validation of clinical significance of examined lymph node count for accurate prognostic evaluation of gastric cancer for the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging system. Chin J Cancer Res. 2018;30(5):477–491.
   PubMed Web of Science ®Google Scholar
• Long B, Yu ZY, Li Q, et al. A systematic review and network meta-analysis protocol of neoadjuvant treatments for patients with gastric cancer. Medicine. 2018;97(15):e0392.
   PubMed Web of Science ®Google Scholar
• Dong Y, Qiu Y, Deng J, et al. Insufficient examined lymph node count underestimates staging in pN3a patients after curative gastrectomy: a multicenter study with external validation. J Cancer Res Clin Oncol. 2020;146(2):515–528.
   PubMed Web of Science ®Google Scholar
• Zhang N, Bai H, Deng J, et al. Impact of examined lymph node count on staging and long-term survival of patients with node-negative stage III gastric cancer: a retrospective study using a Chinese multi-institutional registry with surveillance, epidemiology, and end results (SEER) data validation. Ann Transl Med. 2020;8(17):1075–1075.
   PubMed Web of Science ®Google Scholar
• Cui J, Zhang L, Yang L, et al. The prognostic significance of the treatment response of regional lymph nodes and the refinement of the current TNM staging system in locally advanced rectal cancer after neoadjuvant chemoradiotherapy. Cancer Med. 2020;9(24):9373–9384.
   PubMed Web of Science ®Google Scholar
• Wang CX, Zhuang HB, Shi ZS, et al. Golgi phosphoprotein 3 represents a novel tumor marker for gastric and colorectal cancers. Dis Markers. 2021;2021:1–8.
   Web of Science ®Google Scholar
• Huang KH, Chen MH, Fang WL, et al. The clinicopathological characteristics and genetic alterations of signet-ring cell carcinoma in gastric cancer. Cancers. 2020;12(8):2318.
   PubMed Web of Science ®Google Scholar
• Afaneh C, Levy A, Selby L, et al. Ex vivo lymphadenectomy during gastrectomy for adenocarcinoma optimizes lymph node Yield. J Gastrointest Surg. 2016;20(1):165–171.
   PubMed Web of Science ®Google Scholar
• Yang ZL, Zhu MH, Han XJ, et al. American joint committee on cancer tumor-node-metastasis staging system based on the node ratio can further improve the capacity of prognosis assessment for gastric cancer patients. Front Oncol. 2019;9:329.
   Google Scholar
• Seeruttun SR, Xu L, Wang F, et al. A homogenized approach to classify advanced gastric cancer patients with limited and adequate number of pathologically examined lymph nodes. Cancer Commun (Lond). 2019;39(1):32.
   PubMed Web of Science ®Google Scholar
• Zhao LY, Li CC, Jia LY, et al. Superiority of lymph node ratio-based staging system for prognostic prediction in 2575 patients with gastric cancer: validation analysis in a large single center. Oncotarget. 2016;7(32):51069–51081.
   PubMedGoogle Scholar
• Qiu MZ, Wang ZX, Zhou YX, et al. Proposal for a new TNM stage based on the 7th and 8th American Joint Committee on Cancer pTNM staging classification for gastric cancer. J Cancer. 2018;9(19):3570–3576.
   PubMed Web of Science ®Google Scholar
• Zhu X, Tian X, Yu C, et al. A long non-coding RNA signature to improve prognosis prediction of gastric cancer. Mol Cancer. 2016;15(1):60.
   PubMed Web of Science ®Google Scholar
• Hou Y, Wang X, Chen J. Prognostic significance of metastatic lymph node ratio: the lymph node ratio could be a prognostic indicator for patients with gastric cancer. World J Surg Onc. 2018;16(1):198.
   PubMed Web of Science ®Google Scholar